
Revolution Medicines' cancer drug Rasonque posts record $198M launch in five weeks.
Revolution Medicines' pancreatic cancer drug Rasonque achieved a historic launch, generating $198 million in revenue within its first five weeks on the market. The drug outperformed standard chemotherapy in Phase 3 trials, doubling median survival ra...



